Eikon Therapeutics, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $EIKN in the last 30 days.
See all $EIKN insider activity →Eikon Therapeutics, Inc. (EIKN) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress • TLR7/8 dual-agonist EIK1001 plus pembrolizumab and chemotherapy in first-line, stage 4 non-small cell lung cancer (NSCLC) demonstrates durable e
Eikon Therapeutics (EIKN) reported 63.1% ORR in NSCLC combo trial with EIK1001, pembrolizumab, and chemo. Squamous cohort showed 72.4% ORR, 100% DCR, and 12.9-month median DOR. Phase 2/3 trial ongoing, with interim analysis expected in 2H 2027. Safety profile was consistent with standard of care.
Eikon Therapeutics (EIKN) presented clinical data for its EIK1003, EIK1004, and EIK1005 programs, showing antitumor activity and manageable safety profiles. EIK1003 monotherapy had a 14.3% overall response rate, higher among PARP-inhibitor-naïve participants. Combinations with abiraterone and paclitaxel showed preliminary activity. EIK1004 had a 12.1% response rate with minimal severe toxicities. EIK1005 monotherapy resulted in stable disease for most participants.
Over the past 7 days, AlphAI's AI scored 9 news stories mentioning EIKN (Eikon Therapeutics, Inc.). Coverage has skewed bullish: 9 bullish, 0 neutral, and 0 bearish.
Recent EIKN coverage spans financial news, technology and insider activity.
Positive trial data likely lifts EIKN share price as investors anticipate regulatory filing and potential market approval.
Strong efficacy signals may lift the stock as investors anticipate regulatory filing and potential approval.
Positive early trial data may lift the stock as investors reassess the pipeline's potential.
Positive safety and early efficacy signals may boost investor confidence in Eikon's pipeline.
The abstracts signal upcoming clinical data that could move the stock depending on trial outcomes.
AlphAI scores every news story that mentions EIKN with an AI model for sentiment and relevance, and aggregates insider trades from Eikon Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Eikon Therapeutics, Inc. (EIKN) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress • TLR7/8 dual-agonist EIK1001 plus pembrolizumab and chemotherapy in first-line, stage 4 non-small cell lung cancer (NSCLC) demonstrates durable e
2 min readEikon Therapeutics (EIKN) reported 63.1% ORR in NSCLC combo trial with EIK1001, pembrolizumab, and chemo. Squamous cohort showed 72.4% ORR, 100% DCR, and 12.9-month median DOR. Phase 2/3 trial ongoing, with interim analysis expected in 2H 2027. Safety profile was consistent with standard of care.
2 min readEikon Therapeutics (EIKN) presented clinical data for its EIK1003, EIK1004, and EIK1005 programs, showing antitumor activity and manageable safety profiles. EIK1003 monotherapy had a 14.3% overall response rate, higher among PARP-inhibitor-naïve participants. Combinations with abiraterone and paclitaxel showed preliminary activity. EIK1004 had a 12.1% response rate with minimal severe toxicities. EIK1005 monotherapy resulted in stable disease for most participants.
1 min readEikon Therapeutics, Inc. (EIKN) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress • Initial and updated cohort data from ongoing Phase 1/2 study of highly selective non-brain-penetrant PARP1 inhibitor EIK1003 contin
2 min readEikon Therapeutics (EIKN) announced seven abstracts for the 2026 ESMO Congress, including updates on its cancer-drug pipeline. The presentations cover Phase 1/2 and Phase 2 trials for EIK1001, EIK1003, EIK1004, and EIK1005, targeting lung and prostate cancers among others. The company aims to share clinical findings and progress in its oncology programs.
2 min readHC Wainwright initiated coverage of Eikon Therapeutics with a Buy rating and $23 price target, implying 205% upside from $7.54 close. Analysts cite strong clinical evidence for EIK1001 and EIK1003, and innovative SMT technology platform.
1 min readEikon Therapeutics (EIKN) presented at the Cantor Fitzgerald conference, highlighting its oncology pipeline, including PARP1 inhibitors and TLR7/8 programs. The company reported $531.2M in cash and a $75M quarterly burn rate. Key data for its lead programs is expected in early 2027. Management also discussed expansion into neuroscience, inflammatory disease, and cardiovascular research.
3 min readColumn Group IV GP, LP purchased 89,200 indirectly-held shares of Eikon Therapeutics, Inc. (EIKN) at $11.56 ($1.03M total) on 2026-09-03. Filed jointly with Column Group IV-A, LP (10% owner), Column Group IV, LP (10% owner), Column Group Opportunity III, LP (10% owner), Column Group Opportunity III GP, LP (10% owner), TCG Opportunity III GP, LLC (10% owner), Kutzkey Tim (10% owner) and Svennilson Peter (10% owner).
1 min readLatigo Biotherapeutics and Eikon Therapeutics appointed new executives following their IPOs. Allogene Therapeutics and LB Pharma also announced leadership changes, reflecting broader biotech sector restructuring. These moves are part of organizational development in the public market.
2 min readEikon Therapeutics (EIKN) appointed Dr. Ching-Pin Chang as Executive VP & Chief Scientific Officer. Chang has extensive experience in cardiovascular research and drug discovery. The company focuses on oncology with several clinical-stage drug candidates. EIKN shares are down 1.49% at $11.21.
2 min read
